Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, announced that CEO Michael Halstead will participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit. The virtual event is scheduled for Sept. 23, 2026, at 9 a.m. EDT and will be webcast live. The announcement matters because it gives the company a prominent platform to discuss its proprietary NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity, at a time when the treatment landscape for depression and anxiety remains inadequate for many patients.
Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and is committed to helping minds heal. The company's NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that seek to provide durable improvements in mental health. For investors and industry observers, Halstead's participation in the TD Cowen summit signals that the company is positioning itself as a serious player in the neuropsychiatry space, where novel mechanisms are drawing increasing attention from both clinicians and capital markets.
Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. That program has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, a status reserved for therapies that may offer substantial improvement over existing treatments. The company is also developing HLP004, another proprietary NSA, in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs. The company operates in Canada, the United States, the United Kingdom and Ireland, giving it a multi-jurisdictional footprint that could support regulatory and commercial strategies if its programs succeed.
The implications of the summit appearance extend beyond a single presentation. Major depressive disorder and generalized anxiety disorder affect millions of people worldwide, and existing therapies often fail to produce lasting relief or come with burdensome side effects. If Helus Pharma's NSAs can deliver durable improvements, they could represent a meaningful advance in mental health care. The FDA's Breakthrough Therapy Designation for HLP003 suggests regulators see potential in the approach, and the Phase 3 trial will be a critical test of whether that potential translates into clinical benefit. For a company still in the clinical stage, such milestones are closely watched by investors who weigh scientific risk against the size of the opportunity.
Helus Pharma maintains a newsroom for the latest updates and company information, and its progress can be followed through dedicated channels. Additional details about the company and its pipeline are available through its website and investor resources. The TD Cowen summit provides a timely venue for Halstead to outline the company's strategy and the science behind its NSAs, which could help build awareness among specialists and potential partners.
NetworkNewsWire, a specialized communications platform focused on financial news and content distribution, disseminated the announcement. It is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions. NetworkNewsWire brings clients recognition and brand awareness, and its full terms of use and disclaimers are available on its website.
